Kelly J. Kennedy, a director at Vital Farms, Inc. (NASDAQ:VITL), recently increased his personal holdings in the company by acquiring shares of its common stock. On May 14, 2026, Kennedy executed a purchase of 2,500 shares. The average price paid for these shares was $8.40 per share, though the actual transaction prices varied between $8.28 and $8.40. This single acquisition represented a total investment value of $21,000.
This reported buying activity takes place while the stock is trading close to its 52-week low of $7.95. Over the past twelve months, the equity has seen a decline of 76%. Analysis from InvestingPro suggests that, at current valuation levels, the stock may be undervalued, classifying it among the platform's most undervalued securities.
Following this transaction, Kennedy’s direct ownership stake in Vital Farms common stock increased to 22,927 shares. The timing of this director purchase stands out against a backdrop of mixed corporate performance and analyst sentiment for Vital Farms.
Recent Corporate Performance and Analyst Reactions
In separate news flow, Vital Farms released its first-quarter earnings report for 2026. The results showed that the company reported an earnings per share (EPS) of -$0.03. This figure represented a notable shortfall compared to the projected EPS of $0.16. Despite this significant earnings miss, the company did report a year-over-year increase in revenue, which reached $187.2 million, marking a 15.4% growth.
However, the combination of the poor earnings performance and escalating operating expenses has generated concern among investors. The subsequent analysis from several major analyst firms reflected these concerns through adjustments to ratings and price targets for Vital Farms.
- William Blair downgraded the stock's rating, moving it from Outperform to Market Perform. This action was attributed to the disappointing first-quarter performance coupled with ongoing challenges related to oversupply in the egg industry.
- Telsey also issued a downgrade, changing its assessment from Outperform to Market Perform. Telsey cited both a sharp reduction in the full-year guidance and increasing competition stemming from private label brands.
- Stifel downgraded Vital Farms to Hold from Buy, reducing its price target significantly from $34 to $10. Stifel highlighted persistent supply challenges and limited visibility into when operating conditions might normalize.
- Meanwhile, **Needham** maintained a Buy rating but lowered its price target, adjusting it from $20 down to $13.
These varied developments underscore the broader operational and market challenges confronting the company in the current economic climate.